Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Leqvio | inclisiran | Primary hypercholesterolemia | Active | |||
| Dificid | fidaxomicin | Clostridium difficile infection | Active | |||
| Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active | |||
| Orgovyx | relugolix | Advanced prostate cancer | Active | |||
| Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Active | |||
| Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
| Repatha | evolocumab | Primary hyperlipidemia | Active | |||
| TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Jemperli | dostarlimab | Endometrial cancer | Active |
Last Updated : April 25, 2024